- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07787949
Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects
Evaluation of Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects: A Randomized Clinical Trial
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Periodontitis is a multifactorial inflammatory disease that occurs due to the challenge between the host response and specific periodontal pathogens, leading to a gradual destruction of the periodontal supporting tissues over time.
Different regenerative approaches have been proposed including guided tissue regeneration (GTR); bone grafts, bioactive agents such as enamel matrix derivative (EMD) and platelet concentrates.
Using the minimally invasive nonsurgical technique (MINST) implements magnification with microscope/loupes and delicate instruments, to perform the periodontal debridement with more effective root debridement and less soft tissue trauma. MINST significantly improve the visualization and root decontamination, and at the same time preserve the gingival margin and consequently improve the aesthetic results and tissue stability.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Moustafa A Ahmed, B.D.S
- Telefonnummer: 00201098378998
- E-Mail: 23110295.pg@o6u.edu.eg
Studienorte
-
-
Giza Governorate
-
Giza, Giza Governorate, Ägypten, 12511
- Rekrutierung
- October 6 University (Faculty of Dentistry)
-
Unterermittler:
- Reham L Aggour, MD
-
Kontakt:
- Moustafa A Ahmed, B.D.S
- Telefonnummer: 00201098378998
- E-Mail: 23110295.pg@o6u.edu.eg
-
Unterermittler:
- Shereen F Ahmed, MD
-
Unterermittler:
- Wessam I Shehab, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Patients of both genders >18 years old, medically free of systemic diseases affecting periodontal regeneration.
- Diagnosis of stage III, grade B periodontitis (according to the AAP/EFP classification 2018) with the presence of class II furcation defect in either the maxillary (buccal) or mandibular arch (buccal or lingual) as determined by clinical evaluation and confirmed by radiographic evaluation.
- Gingival margin and interdental bone positioned coronally to the furcation entrance.
- Commitment to maintenance visits and follow-up.
- Absence of primary endodontic lesions.
Exclusion Criteria:
- Patients suffering from any systemic diseases that may affect the outcome of periodontal therapy, including diabetes, immune deficiencies, etc;
- Patients that received periodontal surgical treatments in the past 12 months.
- Smoking (current or in past 5 years)
- Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months prior to periodontal therapy.
- Pregnant and lactating females.
- Teeth with hopeless prognosis
- Third molars
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Positive control group
Patients will receive minimally invasive non-surgical technique (MINST) alone
|
Patients will receive minimally invasive non-surgical technique (MINST) alone
|
|
Experimental: Test group
Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection
|
Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Radiographic Bone Fill at the Furcation Site
Zeitfenster: 6 months after treatment
|
Radiographic bone fill at the furcation site will be assessed using cone-beam computed tomography (CBCT).
The analysis will include measurement of the filled bone volume (FBV) at the furcation area using segmentation.
|
6 months after treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Horizontal Clinical Attachment Level
Zeitfenster: 6 months after treatment
|
Horizontal clinical attachment level will be assessed using periodontal probing at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Vertical Clinical Attachment Level
Zeitfenster: 6 months after treatment
|
Vertical clinical attachment levels will be assessed using periodontal probing at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Probing Pocket Depth
Zeitfenster: 6 months after treatment
|
Probing pocket depth (PPD) will be measured in millimeters from the gingival margin to the base of the periodontal sulcus at six sites per tooth using a UNC-15 periodontal probe.
Measurements will be recorded at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Gingival Margin Location
Zeitfenster: 6 months after treatment
|
The location of the gingival margin will be assessed by measuring the distance from the cemento-enamel junction (CEJ) to the gingival margin.
Measurements will be recorded at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Plaque Index
Zeitfenster: 6 months after treatment
|
Plaque index (PI) will be assessed to evaluate oral hygiene status by measuring dental plaque accumulation in areas adjacent to the gingival margin.
Plaque index will be recorded at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Bleeding on Probing
Zeitfenster: 6 months after treatment
|
Bleeding on probing (BoP) will be assessed by gently inserting a periodontal probe into the gingival sulcus at the base of the interdental papilla and recording the intensity of bleeding after a short delay.
BoP will be assessed at baseline and 6 months after treatment.
|
6 months after treatment
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 23110295
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .